This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Epogin

Roche Holding AG

Drug Names(s): EPOCH, epoetin beta, Recormon/NeoRecormon (EU)

Description: Epogin consists of epoetin beta, a recombinant human erythropoeitin. Epoetin beta has a different structure than epoetin alpha, giving it a longer elimination half-life, allowing for weekly dosing.

Epoetin stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.

Partners: Chugai Pharmaceutical Co., Ltd.


Epogin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug